Technology ID
TAB-4530
Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer
E-Numbers
E-212-2017-0
Lead Inventor
Wiestner, Adrian
Lead IC
NHLBI
Co-Inventors
Baskar, Sivasubramanian
Rader, Christoph
ICs
NHLBI
Applications
Research Materials
Therapeutic Areas
Oncology
Development Stages
Pre-Clinical (in vitro)
This technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK inhibitor, has been shown to normalize T cell dysfunction characteristic of CLL. We show that achieved significantly more killing of ibrutinib-treated CLL cells compared to treatment-naive CLL cells after 3 days of exposure (56.85% versus -3.29% mean specific-killing, p = 0.002), and after 7 days of exposure.
Commercial Applications
Combination therapy of bispecific antibodies in malignancies in combination with kinase inhibitors.
Competitive Advantages
The invention describes a new form of immunotherapy: the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to recruit T cell attack on tumor cells. Our data provide evidence for a superior treatment response of the combined modality.
Licensing Contact: